Maria J Gonzalez Rellan (Chusa)
@chusagzlzrellan.bsky.social
PhD at Rubén Nogueiras lab 🇪🇸 Now Postdoctoral Fellow at Mount Sinai/LTRI, DanielDrucker lab 🇨🇦. Interested in endocrinology and metabolism. MSCA fellow🇪🇺
Reposted by Maria J Gonzalez Rellan (Chusa)
The latest review on #MASH and an overview of resmetirom and semaglutide for moderate to advanced fibrosis jamanetwork.com/journals/jam...
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults: A Review
This Review summarizes the pathogenesis, epidemiology, diagnosis, treatment, and prognosis for adults with metabolic dysfunction–associated steatotic liver disease.
jamanetwork.com
November 11, 2025 at 11:26 AM
The latest review on #MASH and an overview of resmetirom and semaglutide for moderate to advanced fibrosis jamanetwork.com/journals/jam...
Reposted by Maria J Gonzalez Rellan (Chusa)
The latest review on the future of GLP-1 medicines from Prof Bailey @diabetologiajnl.bsky.social link.springer.com/article/10.1...
Pharmacological therapies for type 2 diabetes: future approaches - Diabetologia
Despite the availability of at least nine differently acting classes of glucose-lowering agents, many people with type 2 diabetes do not achieve or maintain sufficiently tight glycaemic control to avo...
link.springer.com
November 1, 2025 at 10:24 AM
The latest review on the future of GLP-1 medicines from Prof Bailey @diabetologiajnl.bsky.social link.springer.com/article/10.1...
Reposted by Maria J Gonzalez Rellan (Chusa)
#GLP1 medicines now address weight loss and other health conditions through innovative formulations and expanded indications, highlighting key questions about their efficacy and safety.
ja.ma/4n81Ptf
ja.ma/4n81Ptf
September 17, 2025 at 1:00 PM
#GLP1 medicines now address weight loss and other health conditions through innovative formulations and expanded indications, highlighting key questions about their efficacy and safety.
ja.ma/4n81Ptf
ja.ma/4n81Ptf
The world of GLP-1 medicines keeps expanding: new molecules, new indications, new mechanisms. Here’s our update @danieljdrucker.bsky.social . An exciting field to watch! @jama.com
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
New Molecules and Indications for GLP-1 Medicines
This Perspective explores recent progress and future directions in glucagon-like peptide-1 medicines.
jamanetwork.com
September 15, 2025 at 4:00 PM
The world of GLP-1 medicines keeps expanding: new molecules, new indications, new mechanisms. Here’s our update @danieljdrucker.bsky.social . An exciting field to watch! @jama.com
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted by Maria J Gonzalez Rellan (Chusa)
Nice overview of the GLP-1 drug family expanding benefits
www.cell.com/cell-reports... @danieljdrucker.bsky.social @chusagzlzrellan.bsky.social
www.cell.com/cell-reports... @danieljdrucker.bsky.social @chusagzlzrellan.bsky.social
The expanding benefits of GLP-1 medicines
GLP-1 medicines, initially developed for blood glucose and weight control, improve
outcomes in people with cardiovascular, kidney, liver, arthritis, and sleep apnea
disorders, actions mediated in part...
www.cell.com
July 15, 2025 at 3:57 PM
Nice overview of the GLP-1 drug family expanding benefits
www.cell.com/cell-reports... @danieljdrucker.bsky.social @chusagzlzrellan.bsky.social
www.cell.com/cell-reports... @danieljdrucker.bsky.social @chusagzlzrellan.bsky.social
GLP-1 medicines have shown benefits in conditions beyond T2D and obesity, including CVD, CKD, and MASLD. Here, @danieljdrucker.bsky.social and I summarize and discuss clinical evidence and possible mechanisms of action 😄👇🏼👇🏼
www.cell.com/cell-reports...
www.cell.com/cell-reports...
The expanding benefits of GLP-1 medicines
GLP-1 medicines, initially developed for blood glucose and weight control, improve
outcomes in people with cardiovascular, kidney, liver, arthritis, and sleep apnea
disorders, actions mediated in part...
www.cell.com
July 15, 2025 at 5:11 PM
GLP-1 medicines have shown benefits in conditions beyond T2D and obesity, including CVD, CKD, and MASLD. Here, @danieljdrucker.bsky.social and I summarize and discuss clinical evidence and possible mechanisms of action 😄👇🏼👇🏼
www.cell.com/cell-reports...
www.cell.com/cell-reports...
🚨 #MASH #MASLD : Semaglutide at a dose of 2.4 mg induces resolution of steatohepatitis without worsening of fibrosis in 62.9% of patients after 72 weeks, and reduces liver fibrosis without worsening of steatohepatitis in 36.8% of patients!!
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | NEJM
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment
of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase
3, multicenter, randomize...
www.nejm.org
May 1, 2025 at 12:11 AM
🚨 #MASH #MASLD : Semaglutide at a dose of 2.4 mg induces resolution of steatohepatitis without worsening of fibrosis in 62.9% of patients after 72 weeks, and reduces liver fibrosis without worsening of steatohepatitis in 36.8% of patients!!
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
www.nature.com/articles/s41...
New review from @danieljdrucker.bsky.social about GLP-1-based medicines, discussing optimization of pharmacokinetics and tolerability, engagement of new therapeutically useful pathways and safety aspects 👇🏼👇🏼
New review from @danieljdrucker.bsky.social about GLP-1-based medicines, discussing optimization of pharmacokinetics and tolerability, engagement of new therapeutically useful pathways and safety aspects 👇🏼👇🏼
GLP-1-based therapies for diabetes, obesity and beyond - Nature Reviews Drug Discovery
GLP-1-based therapies represent highly effective treatments for patients with type 2 diabetes and obesity. This Review profiles established and emerging GLP-1-based medicines, focusing on novel GLP-1 ...
www.nature.com
April 25, 2025 at 1:48 PM
www.nature.com/articles/s41...
New review from @danieljdrucker.bsky.social about GLP-1-based medicines, discussing optimization of pharmacokinetics and tolerability, engagement of new therapeutically useful pathways and safety aspects 👇🏼👇🏼
New review from @danieljdrucker.bsky.social about GLP-1-based medicines, discussing optimization of pharmacokinetics and tolerability, engagement of new therapeutically useful pathways and safety aspects 👇🏼👇🏼
Reposted by Maria J Gonzalez Rellan (Chusa)
Un estudio #CiMUS- @usc.gal, Clínic-IDIBAPS y Universidad Católica de Lovaina acaba de demostrar que el #cerebro puede modular la composición de la microbiota intestinal y hacerlo en cuestión de horas.
👉 shre.ink/MQnX
#FondosEuropeos #RedeCiGUS #microbiotaintestinal #cerebro
👉 shre.ink/MQnX
#FondosEuropeos #RedeCiGUS #microbiotaintestinal #cerebro
April 22, 2025 at 10:12 AM
Un estudio #CiMUS- @usc.gal, Clínic-IDIBAPS y Universidad Católica de Lovaina acaba de demostrar que el #cerebro puede modular la composición de la microbiota intestinal y hacerlo en cuestión de horas.
👉 shre.ink/MQnX
#FondosEuropeos #RedeCiGUS #microbiotaintestinal #cerebro
👉 shre.ink/MQnX
#FondosEuropeos #RedeCiGUS #microbiotaintestinal #cerebro
👇🏼👇🏼👇🏼😊😊👏🏻👏🏻
The origins of GLP-1 discovery science started ~40 yrs ago in Boston & Copenhagen. The remarkable GLP-1 medicine story continues to unfold-featured this year April 2, 2 pm at the Triennial Warren Prize Symposium at Mass General @harvardmed.bsky.social #diabetes #Obesity massgeneral.link/warren2025
March 31, 2025 at 1:24 AM
👇🏼👇🏼👇🏼😊😊👏🏻👏🏻
Reposted by Maria J Gonzalez Rellan (Chusa)
The reduction in CRP with oral semaglutide is near maximal at the first time point measured, 13 weeks, whereas body weight continues to decline over time, again dissociating weight loss from the anti-inflammatory actions of GLP-1 medicines www.nejm.org/doi/full/10....
March 31, 2025 at 12:28 AM
The reduction in CRP with oral semaglutide is near maximal at the first time point measured, 13 weeks, whereas body weight continues to decline over time, again dissociating weight loss from the anti-inflammatory actions of GLP-1 medicines www.nejm.org/doi/full/10....
Reposted by Maria J Gonzalez Rellan (Chusa)
The SOUL CVOT with oral semaglutide #T2D 14% reduction in MACE. The mean follow-up was 47.5 months; NNT over 3 yrs=50;2.95 kg placebo-subtracted #weightloss 26.9% baseline use of SGLT2i #CVD #ACC2025 www.nejm.org/doi/full/10....
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes | NEJM
The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor
agonist, has been established in persons with type 2 diabetes and high cardiovascular
risk. An assessment of the ca...
www.nejm.org
March 29, 2025 at 6:44 PM
The SOUL CVOT with oral semaglutide #T2D 14% reduction in MACE. The mean follow-up was 47.5 months; NNT over 3 yrs=50;2.95 kg placebo-subtracted #weightloss 26.9% baseline use of SGLT2i #CVD #ACC2025 www.nejm.org/doi/full/10....
Reposted by Maria J Gonzalez Rellan (Chusa)
Es un orgullo para este Centro que su personal investigador sea un espejo en el que la juventud pueda verse reflejada creando así referentes que, como en el caso de Olga, lleguen lejos gracias al talento y el esfuerzo.
March 8, 2025 at 3:32 PM
Es un orgullo para este Centro que su personal investigador sea un espejo en el que la juventud pueda verse reflejada creando así referentes que, como en el caso de Olga, lleguen lejos gracias al talento y el esfuerzo.
Reposted by Maria J Gonzalez Rellan (Chusa)
Desde el CiMUS queremos felicitar a nuestra investigadora Olga Barca Mayo por el premio 🏆 #8M que le fue otorgado ayer por el Concello de Negreira.
¡Nuestra más sincera enhorabuena, Olga!👏
👉https://bit.ly/4he37Pr
@usc.gal #8M #diadelasmujeres
¡Nuestra más sincera enhorabuena, Olga!👏
👉https://bit.ly/4he37Pr
@usc.gal #8M #diadelasmujeres
March 8, 2025 at 3:32 PM
Desde el CiMUS queremos felicitar a nuestra investigadora Olga Barca Mayo por el premio 🏆 #8M que le fue otorgado ayer por el Concello de Negreira.
¡Nuestra más sincera enhorabuena, Olga!👏
👉https://bit.ly/4he37Pr
@usc.gal #8M #diadelasmujeres
¡Nuestra más sincera enhorabuena, Olga!👏
👉https://bit.ly/4he37Pr
@usc.gal #8M #diadelasmujeres